Please assess the completion status of the following clinical trial:

Trial Title: A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronically infected with HCV genotype 1~* Treatment naive or treatment non-responders or treatment intolerant~* HCV RNA viral load of ≥10\*5\* IU/mL~* BMI 18 to 35 kg/m²~Exclusion Criteria:~* Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with HCV infection~* Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug~* Co-infection with HIV or HBV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): BMS-791325 (100 mg)~or~placebo match for (100 mg)
- 2 (Type: EXPERIMENTAL): BMS-791325 (300 mg)~or~placebo match for (300 mg)
- 3 (Type: EXPERIMENTAL): BMS-791325 (900 mg)~or~placebo match for (900 mg)
- 4 (Type: EXPERIMENTAL): BMS-791325 (potential dose between 10-800 mg)~or~placebo match for (10-800 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).